Insider Selling: Beam Therapeutics (NASDAQ:BEAM) CEO Sells $589,250.00 in StockDefense World · 6 days ago
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?The Motley Fool · Oct 17, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAMPRNewsWire · Oct 15, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAMGlobeNewsWire · Oct 13, 2026
Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a FuseBenzinga · Oct 13, 2026
Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual CongressGlobeNewsWire · Oct 13, 2026Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$1.11 | -$1.18 | Miss |
| May 7, 2026 | -$0.87 | -$0.91 | Miss |
| Feb 24, 2026 | -$1.13 | -$0.10 | Beat |
| Nov 4, 2025 | -$0.98 | -$1.10 | Miss |
| Aug 5, 2025 | -$1.04 | -$1.00 | Beat |
| May 6, 2025 | -$1.11 | -$1.24 | Miss |